Spruce Biosciences
Logotype for Spruce Biosciences Inc

Spruce Biosciences (SPRB) investor relations material

Spruce Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Spruce Biosciences Inc
3rd Annual Guggenheim Healthcare Innovation Conference summary10 Nov, 2026

Lead asset and regulatory pathway

  • Tralesinidase alfa is a CSF-delivered enzyme replacement therapy fused to truncated IGF-2 for neuronal and lysosomal penetration; delivery is weekly or every other week via port and Ommaya reservoir, with profound heparan sulfate effects and supportive safety and efficacy data.

  • BLA submission is planned for December under the accelerated-approval pathway, using heparan sulfate non-reducing ends as the primary endpoint; FDA said the biomarker is reasonably likely to predict clinical benefit, while acceptance remains a review issue.

  • FDA pre-BLA meetings covered CMC and clinical content; no AdCom requirement has been discussed or signaled by FDA.

Manufacturing and clinical evidence

  • First drug-substance and drug-product PPQ batches are planned for the BLA; the second PPQ will be submitted during review, with analytical reports targeted before the mid-cycle meeting; drug-product manufacturing transferred from Vetter to Samsung Biologics for qualification.

  • Confirmatory trial is initiated and must be underway at BLA submission, but need not be fully recruited by launch; expanded access is intended to provide product access before commercial availability.

  • Confirmatory-trial primary endpoint is Bayley cognitive raw score; analyses include sensitivity methods and propensity matching on age and baseline cognition to address imbalances against natural-history patients.

  • NfL, GM2, GM3 and other biomarker findings are planned for presentation at the WORLD meeting in February in San Diego.

Market and launch plans

  • Preliminary U.S. claims analysis identified ~1,400 MPS III patients, with an estimated ~450 diagnosed MPS IIIB; incidence-based estimates span 250 to ~2,000 patients.

  • Five U.S. centers of excellence specialize in MPS; a concentrated sales team is expected to reach the patient pool through these centers.

  • Planned cadence is BLA submission in December, acceptance in February and potential approval around August; Rare Pediatric Disease designation would qualify for a PRV, with proceeds planned to fund U.S. commercialization.

  • European approval remains a goal; the initiative is being revamped starting in Q4, with local distributors, partners or named-patient programs under consideration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Spruce Biosciences earnings date

Logotype for Spruce Biosciences Inc
Q4 20269 Mar, 2027
Spruce Biosciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Spruce Biosciences earnings date

Logotype for Spruce Biosciences Inc
Q4 20269 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Spruce Biosciences Inc. is a biopharmaceutical company developing and commercializing therapies for rare endocrine disorders. The company's leading product candidate, tildacerfont, is a non-steroidal therapy designed to improve disease control and reduce steroid dependency in patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is under clinical trial for both adult and pediatric classic CAH, as well as for females with polycystic ovary syndrome in a separateclinical trial. Spruce Biosciences has entered into strategic partnerships, including a license agreement with Eli Lilly and Company for research, development, and commercialization of compounds, and a collaboration and license agreement with Kaken Pharmaceutical for the treatment of CAH in Japan. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol SPRB.